论文部分内容阅读
药物洗脱支架(DES)在降低支架术后靶血管再狭窄中疗效显著,然而据悉其并不一定适用于伴有房颤(AF)的冠心病患者,因后者被认为系高危人群,亦即尤其是在其选用理想抗血栓治疗策略以防治卒中、支架内血栓形成和再发心肌缺血与降低相关出血高危风险等获益与风险间平衡的确切关系尚未清楚。本文意就在伴AF的冠心病患者中选用DES治疗的有效及安全性与选用金属裸支架(BMS)进行了对照分析。
Drug-eluting stents (DES) have been shown to be effective in reducing target vascular restenosis after stenting, however, it is reported that they are not necessarily applicable to patients with coronary artery disease associated with atrial fibrillation (AF) because they are considered to be at high risk In other words, the precise relationship between the benefits and risk balance of their choice of ideal anti-thrombotic strategies to prevent stroke, stent thrombosis and myocardial ischemia-reperfusion, and to reduce the risk of associated bleeding remains unclear. This article intended to use AF in the treatment of coronary heart disease patients with DES treatment of effective and safety and selection of bare metal stent (BMS) were analyzed.